Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00567359
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 140
- Registration Number
- NCT00564720
- Locations
- 🇬🇷
Metaxa's Anticancer Hospital of Piraeus, 1st Department of Medical Oncology, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupolis, Greece
🇬🇷Errikos Ntynan General Hospital, Athens, Greece
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT00563784
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00553800
- Locations
- 🇺🇸
AtlantiCare Regional Medical Center, Galloway, New Jersey, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Virtua Health Cancer Program at Memorial, Mount Holly, New Jersey, United States
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 247
- Registration Number
- NCT00550173
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00547105
- Locations
- 🇺🇸
University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States
🇺🇸Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00543842
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 7
- Registration Number
- NCT00539617
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 224
- Registration Number
- NCT00536640
- Locations
- 🇩🇪
Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
🇩🇪Asklepios Klinik Harburg, Hamburg, Germany
🇩🇪Charite´ Mitte, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.